She succumbed to her disease 11 months after the initial diagnosis. Our work provides evidence supporting the use of crizotinib in patients with metastatic LUAD harboring GHR-ALK.
3 years ago
Clinical • Journal
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)